Structure Therapeutics (GPCR) maintains a Buy rating after its oral GLP-1 drug aleniglipron showed up to 16.2% weight loss in Phase 2b trials targeting obesity. The drug demonstrated a favorable safety profile and is now in Phase 3, with pivotal data expected by Q4 2028. GPCR's $1.34 billion cash reserve is sufficient to fund Phase 3 completion, supporting its development despite high R&D costs. Risks include competition and potential Phase 3 failure, but the drug's efficacy and cost advantages suggest blockbuster potential.
Wedbush increased its price target for Scholar Rock to $64 from $58 and kept an "Outperform" rating ahead of the FDA's September 30 decision on Scholar Rock's investigational SMA drug, apitegromab. This drug could be the first muscle-targeted therapy...
IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, will conduct a 1-for-30 reverse stock split on August 27, 2026. This move aims to increase its share price, currently at $0.11, to meet the Nasdaq Capital Market's minimum...
Buckle, Inc. reported strong Q2 earnings with an EPS of $0.87, surpassing analyst estimates of $0.81, and revenue of $319.82 million, slightly above expectations. The company saw a 4.6% increase in net sales, driven by growth in both comparable-store...
KE Holdings Inc. reported Q2 2026 earnings with an EPS of $0.42, surpassing the $0.31 consensus estimate. Although revenue declined 5.7% year-over-year to about $3.60 billion, the company doubled its net income thanks to effective cost controls and o...
Tesla reported a 26% year-over-year revenue increase despite a 23% drop in its stock price this year. The company remains a leader in the electric vehicle market, supported by growth opportunities in robotaxi, robotics, and AI sectors. However, Tesla...
